[Interferons--its method of administration and adverse effect related to pharmacokinetics ].
The potential role of interferons in the treatment of malignant diseases is currently being evaluated. This paper reviews experimental and clinical findings regarding pharmacokinetics, method of administration, and side reactions of interferons. Interferon in the blood is rapidly cleared from the circulation. Intramuscular injection of alpha-interferon causes low but stable interferon levels in the blood. However, in the case of beta-interferon, interferon is never detected consistently in the blood after intramuscular or subcutaneous administration. The studies with animal models suggest that doses higher than those given in current clinical trials will be necessary to obtain clearly beneficial effects in human. The maximum safely tolerated daily dose is appreciably higher than that used in most previous studies, although even at this level, considerable toxicity may be encountered. Adequate method of administration, route, dose and interval are not yet established at all. Exact mechanism of anticancer activity is not yet well defined. The most frequent side reaction is fever. However, the exact mechanism to cause these side reactions is also not yet clarified. Dose limiting central nervous system toxicities, hypotension, hypocalcaemia etc. are occasionally encountered in some instances. Antibody to interferon is demonstrated in some cases. Purification of interferon does not always causes reduction of side reactions. The treatment of cancer cases with interferon has just started and there are many problems to be solved. However, therapeutic beneficial may be achieved in the treatment of malignant tumors by appropriate combinations of interferon with conventional treatment. More laboratory studies as well as carefully controlled clinical observations are warranted.
D000818:Animals; D004334:Drug Administration Schedule; D001068:Feeding and Eating Disorders / Q000209:etiology; D005334:Fever / Q000209:etiology; D006801:Humans; D007269:Injections, Intra-Arterial; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood*; D007700:Kinetics; D051379:Mice; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D011817:Rabbits; D014839:Vomiting / Q000209:etiology
D007370:Interferon Type I